Cipher Pharma (CPHR) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Cipher Pharma (CPHR) Launches Actikerall in Canada
February 22, 2016 7:05 AM ESTCipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced the Canadian launch of Actikerall (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused by exposure to ultraviolet radiation2. Cipher... More
